Table 3.

Treatment perceptions

	Treatment Groups
	Montelukast		Placebo		P-values*
	Enhanced	Neutral	Enhanced	Neutral	Message Effect	Drug Effect	Interaction Drug x Message
N	119	116	115	117
Statement	Mean value at baseline (standard deviation) †
	Mean change from baseline (95% Confidence Interval)
Singulair (Montelukast) is an effective drug in helping control asthma.	6.2 (1.7) 0.9 (0.5, 1.3)	6.3 (1.6) 0.5 (0.2., 0.8)	6.3 (1.6) 0.9 (0.6, 1.2)	6.4 (1.6) 0.2 (−0.1, 0.5)	0.001	0.35	0.47
If I were to take Singulair (Montelukast), it would help my asthma	6.2 (1.7) 1.0 (0.7, 1.4)	6.2 (1.5) 0.5 (0.2, 0.8)	6.2 (1.5) 0.7 (0.4, 1.0)	6.3 (1.4) 0.0 (−0.3, 0.2)	<0.001	0.01	0.40
Singulair (Montelukast) is a weak drug for asthma.	4.0 (1.5) −0.7 (−1.1, −0.4)	4.1 (1.6) −0.5 (−0.8, −0.2))	4.0 (1.4) −0.7 (−1, −0.4)	4.1 (1.7) −0.3 (−0.6, 0.0)	0.04	0.56	0.73
Singulair (Montelukast) is likely to help people with asthma	6.6 (1.6) 0.7 (0.4, 1.1)	6.8 (1.4) 0.2 (0.0, 0.5)	6.6 (1.4) 0.6 (0.4, 0.9)	6.6 (1.4) 0.2 (0.0, 0.5)	0.001	0.73	0.71

^*P-values presented are adjusted for clinic. Message effect = Effect of enhanced message independent of drug. Drug Effect = Effect of montelukast independent of message type. The interaction P-value evaluates for whether the drug effect is modified by the message effect

^†Baseline mean and difference from baseline are based on ordinal scale score of 1 to 9, strongly disagree to strongly agree, 5 is neutral.